Compare GNLX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLX | IMNM |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 1.8B |
| IPO Year | 2023 | 2020 |
| Metric | GNLX | IMNM |
|---|---|---|
| Price | $4.35 | $22.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $19.75 | ★ $31.44 |
| AVG Volume (30 Days) | 146.6K | ★ 2.9M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $5.15 |
| 52 Week High | $8.54 | $25.30 |
| Indicator | GNLX | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 61.19 |
| Support Level | $4.10 | $19.37 |
| Resistance Level | $4.37 | $25.30 |
| Average True Range (ATR) | 0.29 | 1.48 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 39.21 | 54.24 |
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.